Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F Di Raimondo

Showing results (51-60 of 54) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 54 results.
Leukemia|August 30, 2016
Treatment and outcome of 2904 CML patients from the EUTOS population-based registryV S Hoffmann, M Baccarani, J Hasford, et al.
Leukemia|March 19, 2015
The EUTOS population-based registry: incidence and clinical characteristics of 2904 CML patients in 20 European CountriesV S Hoffmann, M Baccarani, J Hasford, et al.
The New England Journal of Medicine|August 10, 2012
Treatment of older patients with mantle-cell lymphomaH C Kluin-Nelemans, E Hoster, O Hermine, et al.
ESMO Open|January 8, 2025
Outcomes and prognostic indicators in daratumumab-refractory multiple myeloma: a multicenter real-world study of elotuzumab, pomalidomide, and dexamethasone in 247 patientsE A Martino, S Palmieri, M Galli, et al.
Pageof 6

Showing results (51-60 of 54) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 54 results.
Leukemia|August 30, 2016
Treatment and outcome of 2904 CML patients from the EUTOS population-based registryV S Hoffmann, M Baccarani, J Hasford, et al.
Leukemia|March 19, 2015
The EUTOS population-based registry: incidence and clinical characteristics of 2904 CML patients in 20 European CountriesV S Hoffmann, M Baccarani, J Hasford, et al.
The New England Journal of Medicine|August 10, 2012
Treatment of older patients with mantle-cell lymphomaH C Kluin-Nelemans, E Hoster, O Hermine, et al.
ESMO Open|January 8, 2025
Outcomes and prognostic indicators in daratumumab-refractory multiple myeloma: a multicenter real-world study of elotuzumab, pomalidomide, and dexamethasone in 247 patientsE A Martino, S Palmieri, M Galli, et al.
Pageof 6